TP53 and rectal cancer: Given that CTDSP2 is rarely mutated in the untreated TCGA rectal cancer set (2/132), its mutation, along with APC, KRAS, TP53 and NFKBIZ mutations, might help predict CRT resistance in locally advanced rectal cancer.